Modulation of oxidative stability of haemoglobin inside liposome-encapsulated haemoglobin

被引:4
|
作者
Awasthi, Vibhudutta [1 ]
Yadav, Vivek R. [1 ]
Goins, Beth [2 ]
Phillips, William T. [2 ]
机构
[1] Univ Oklahoma, Hlth Sci Ctr, Coll Pharm, Oklahoma City, OK 73117 USA
[2] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA
基金
美国国家卫生研究院;
关键词
haemoglobin; transfusion; methaemoglobin; oxygen carriers; liposomes; catalase; BLOOD SUBSTITUTES; OXYGEN CARRIER; TRANSFUSION MEDICINE; FUTURE GENERATIONS; CELL; METHEMOGLOBIN; RESUSCITATION; POLYHEMOGLOBIN; REDUCTION; VESICLES;
D O I
10.3109/02652048.2012.752535
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
The major hurdle in the formulation of liposome-encapsulated haemoglobin (LEH) is the oxidation of haemoglobin (Hb) into methaemoglobin during storage and after administration. In order to reduce this oxidative degradation, we tested various reducing conditions in the presence of catalase. We found that at 37 degrees C more than 50% of Hb oxidized to methaemoglobin within 24 h, whereas in presence of catalase, the oxidation was significantly reduced. The effect of catalase was further enhanced by a reduction mixture containing beta-NAD, d-glucose, adenine, inosine, MgCl2, KCl, KH2PO4 and Na2HPO4; only 14% methaemoglobin was generated in the presence of catalase and reduction mixture. Contrary to the expectation, glutathione, deferoxamine and homocysteine enhanced Hb oxidation. The presence of CRM inside liposomes (250 nm) significantly decreased Hb oxidation. The results suggest that catalase and a well-defined mixture of co-factors may help control Hb oxidation for improvement in the functional life of LEH.
引用
收藏
页码:470 / 478
页数:9
相关论文
共 50 条
  • [1] STABILITY OF LIPOSOME-ENCAPSULATED OXYHEMOGLOBIN IN PLASMA
    KURANTSINMILLS, J
    FUJIMOTO, LJ
    LEONDARIDIS, L
    MUESING, R
    BIOPHYSICAL JOURNAL, 1986, 49 (02) : A139 - A139
  • [2] Differentially increased IL-6 mRNA expression in liver and spleen following injection of liposome-encapsulated haemoglobin
    Zhu, XL
    Pacheco, ND
    Dick, EJ
    Rollwagen, FM
    CYTOKINE, 1999, 11 (09) : 696 - 703
  • [3] Liposome-encapsulated antibiotics
    Salem, II
    Flasher, DL
    Düzgünes, N
    LIPOSOMES, PT E, 2005, 391 : 261 - 291
  • [4] Liposome-encapsulated allergens
    delPrado, JM
    CLINICAL AND EXPERIMENTAL ALLERGY, 1996, 26 (08): : 982 - 982
  • [5] Liposome-encapsulated carbapenems
    Drulis-Kawa, Z
    Gubernator, J
    Kostyn, K
    Doroszkiewicz, W
    Kozubek, A
    CELLULAR & MOLECULAR BIOLOGY LETTERS, 2002, 7 (02) : 281 - 281
  • [6] Characterization and stability of various liposome-encapsulated enoxacin formulations
    Fang, JY
    Lin, HH
    Hsu, LR
    Tsai, YH
    CHEMICAL & PHARMACEUTICAL BULLETIN, 1997, 45 (09) : 1504 - 1509
  • [7] EFFICACY OF LIPOSOME-ENCAPSULATED BUPIVACAINE
    DJORDJEVICH, L
    IVANKOVICH, AD
    CHIGURUPATI, R
    WORONOWICZ, A
    MCCARTHY, R
    ANESTHESIOLOGY, 1986, 65 (3A) : A185 - A185
  • [8] STUDIES ON LIPOSOME-ENCAPSULATED HEPARIN
    SAKON, M
    KIM, TD
    KAWASAKI, T
    KAMBAYASHI, J
    MORI, T
    THROMBOSIS AND HAEMOSTASIS, 1985, 54 (01) : 33 - 33
  • [9] UPTAKE OF LIPOSOME-ENCAPSULATED AGENTS
    SZOKA, FC
    JONES, CS
    METHODS IN ENZYMOLOGY, 1987, 149 : 143 - 147
  • [10] IMMUNOPHARMACOLOGY OF LIPOSOME-ENCAPSULATED MURAMYLPEPTIDE
    FROST, H
    FANKHAUSER, P
    GRAEPEL, P
    SCHUMANN, G
    DUKOR, P
    TOXICOLOGICAL AND IMMUNOLOGICAL ASPECTS OF DRUG METABOLISM AND ENVIRONMENTAL CHEMICALS, 1988, 22 : 93 - 100